Skip to main content
Premium Trial:

Request an Annual Quote

BCCA's Genome Sciences Centre Joins Illumina Genome Network


The British Columbia Cancer Agency's Michael Smith Genome Sciences Centre has joined the Illumina Genome Network as a provider of human whole-genome sequencing services, Illumina said this week.

Through the IGN, the company offers human genome sequencing services to researchers, as of this summer priced at $5,000 per genome for projects of at least 10 samples, and $4,000 per genome for projects of at least 50 samples.

Existing members of the IGN are the University of Washington Department of Genome Sciences, the National Center for Genome Resources in New Mexico, the Macrogen/Genomic Medicine Institute in Korea, and Illumina's own FastTrack services lab.

Illumina had already announced GSC's membership during its third-quarter earnings call in October (IS 10/25/2011).

All IGN partners have been certified by Illumina as service providers and possess at least 10 HiSeq 2000 or Genome Analyzer sequencers.

According to its website, the GSC currently has 12 HiSeq 2000 systems. But the center also installed a large number of SOLiD systems from Illumina's rival, Life Technologies, purchasing a total of 10 SOLiDs for whole-genome sequencing of cancer samples last year (IS 4/13/2010).

Marco Marra, the center's director, was not available before deadline for an update on the GSC's sequencing equipment.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.